ENHANCE Phase 3 Validates Single-Dose Regimen

TG Therapeutics announced positive ENHANCE Phase 3 results validating a single-infusion regimen for Briumvi. Goldman Sachs maintains a Neutral rating with a $41 target, shifting focus toward upcoming subcutaneous formulation data.

Key Takeaways

• 1.The ENHANCE Phase 3 trial met its primary goal, demonstrating bioequivalence between a single 600mg infusion and the approved split-dose regimen for Briumvi.
• 2.Shift in physician preference toward at-home administration makes the subcutaneous (SC) formulation the critical driver for future adoption.
• 3.Upcoming catalysts include initial PK data for the subcutaneous formulation in the coming weeks and Phase 3 data in late 2026 or early 2027.

Table of Contents

• Valuation & Risks
• Disclosure Appendix
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Distribution of ratings/investment banking relationships
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures
• Global product; distributing entities
• General disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial